Chris Gibson, Recursion CEO (Vaughn Ridley/Sportsfile for Web Summit via Getty Images)
August 29, 2024 10:00 AM EDT
R&D
AI
In Focus

Re­cur­sion nears ‘mo­ment of truth’ with first key da­ta, kick­ing off 18-month flur­ry of read­outs

Andrew Dunn

Senior Biopharma Correspondent

Max Gelman

Senior Editor

Af­ter years of talk­ing up ar­ti­fi­cial in­tel­li­gence’s po­ten­tial to help make drugs, Re­cur­sion will fi­nal­ly bring da­ta to the ta­ble — and lots of it. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times